Table 2.
Controlled trials of RTX in SSc-ILD.
| References | No of patients | Disease | RTX scheme | Follow up | Outcomes | Safety of RTX |
|---|---|---|---|---|---|---|
| Daoussis et al. (18) | 8 RTX vs. 6 Control | SSc | Lymphoma scheme | 1 y | Improved PFTs and stable HRCT score in favor of RTX | 3 serious AE/2 lung infections, 1 infusion reaction |
| Jordan et al. (19) | 25 RTX vs. 25 control | SSc | RA scheme | 6 m | Increased FVC, stable DLCO in RTX group | 11/53 infections No other serious AE |
| Daoussis et al. (20) | 33 RTX vs. 18 control | SSc | Lymphoma scheme | 7 y | Improved FVC, stable DLCO vs. control | 3 serious infections, 2 infusion reactions, 5 deaths |
| Boonstra et al. (21) | 8 RTX vs. 8 con | SSc | RA scheme | 2 y | Stable PFTs and HRCT similar to control group | 7 serious AE in RTX(infusion reaction) vs. 4 serious AE in control (weight loss) |
| Eustar et al. (22) | 254 RTX vs. 9,575 control | SSc | RA scheme (n = 203) lymphoma scheme (n = 4) else (n = 27) | 2 y | Stable PFTs similar to control/steroid reduction vs. control | 36/254 serious AE, 24/254 discontinue, 6 deaths unrelated |
| Theibaut et al. (24) | 23 RTX vs. 26 non-RTX | SSc | RA scheme | 2 y | Improved PFTs | Infusion reactions, mild infections/2 deaths |
| Sircar et al. (23) | 30 RTX vs. 60 CYC | SSc | RA scheme | 6 m | Improved FVC on RTX vs. control | RTX AE 9/30 vs. CYC AE 21/30 |